Skip to main content
Michael Friedman, MD, Pathology, Tampa, FL

Michael I. Friedman MD

Cytopathology, Anatomic Pathology, Clinical Pathology


Physician

Join to View Full Profile
  • 3001 W Dr Martin Luther King Jr BlvdTampa, FL 33607

  • Phone+1 813-870-4206

  • Fax+1 813-870-4853

Are you Dr. Friedman?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Michael Friedman, MD is a board certified pathologist in Tampa, Florida. He is currently licensed to practice medicine in Florida, Georgia, and Ohio.

Education & Training

  • Emory University School of Medicine
    Emory University School of MedicineFellowship, Cytopathology, 1992 - 1994
  • The MetroHealth System/Case Western Reserve University
    The MetroHealth System/Case Western Reserve UniversityResidency, Pathology-Anatomic and Clinical, 1988 - 1992
  • Mount Sinai Medical Center of Cleveland
    Mount Sinai Medical Center of ClevelandInternship, Transitional Year, 1987 - 1988
  • Stellenbosch University Faculty of Medicine
    Stellenbosch University Faculty of MedicineClass of 1985

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1994 - 2026
  • GA State Medical License
    GA State Medical License 1991 - 1995
  • OH State Medical License
    OH State Medical License 1989 - 1992
  • TN State Medical License
    TN State Medical License 1988 - 1991
  • Anatomic Pathology & Clinical Pathology
    American Board of Pathology Anatomic Pathology & Clinical Pathology
  • Cytopathology
    American Board of Pathology Cytopathology

Press Mentions

  • First Chimeric Antigen Receptor (CAR) T Cell Therapy Targeting B Cell-Activating Factor Receptor (BAFF-R) Eradicates Blood Cancers That Relapsed After CD19 CAR T Therapies
    First Chimeric Antigen Receptor (CAR) T Cell Therapy Targeting B Cell-Activating Factor Receptor (BAFF-R) Eradicates Blood Cancers That Relapsed After CD19 CAR T TherapiesSeptember 25th, 2019
  • First CAR T-cell Therapy Targeting B Cell-Activating Factor Receptor Eradicates Blood Cancers
    First CAR T-cell Therapy Targeting B Cell-Activating Factor Receptor Eradicates Blood CancersSeptember 25th, 2019
  • City of Hope Clinical and Laboratory Investigators Present New Research at the 60
    City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
  • Join now to see all